[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.194.83. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 77
Citations 0
In This Issue of JAMA Oncology
August 2019

Highlights

JAMA Oncol. 2019;5(8):1081. doi:10.1001/jamaoncol.2018.4773
Research

Poly(adenosine diphosphate-ribose) polymerase inhibitor and anti–programmed death receptor 1 therapy have limited clinical activity for advanced triple-negative breast cancer (TNBC). Vinayak et al conducted a phase 2 study of niraparib plus pembrolizumab to assess its clinical activity and safety in patients with advanced or metastatic TNBC. Results showed more responses in patients with BRCA mutations than in those with wild-type tumors. Odunsi and Pejovic provide an Editorial.

Editorial and Related Article

Some birth defects are strongly associated with childhood cancer, but comprehensive evaluation of childhood cancer risk has been limited. Lupo et al performed a multistate, population-based, registry linkage study to identify birth defect–childhood cancer associations. Results showed that the number of birth defects diagnosed was directly associated with cancer risk in children with nonchromosomal birth defects. These findings may guide cancer screening in children with birth defects. Spector and Olshan provide an Editorial.

Editorial

Locoregionally advanced head and neck squamous cell cancer (HNSCC) is treated curatively; however, risk of recurrence remains high among some patients. Burtness et al performed a phase 3, double-blind clinical trial to assess whether afatinib administered after chemoradiotherapy (CRT) would improve disease-free survival (DFS) in patients with HNSCC. Results showed that afatinib after CRT did not improve DFS and was associated with more adverse events than placebo.

The use of anti–human epidermal growth factor receptor 2 (HER2) therapy as an adjuvant regimen in patients with curable HER2-positive advanced gastroesophageal cancer has not yet been examined. Smyth et al conducted a phase 2, open-label trial to assess the safety of adding lapatinib to epirubicin, cisplatin, and capecitabine chemotherapy. Results showed that lapatinib administration was feasible and did not compromise operative management; however, the toxic effects exceeded predefined acceptable parameters.

Biomarker assays have been used to predict response to programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint blockade, but relative diagnostic performance of the assays has not been established. Lu et al conducted a meta-analysis to study the diagnostic accuracy of 4 biomarker assays in predicting clinical response to anti–PD 1/PD-L1 therapies. Results showed that all assays had comparable negative predictive values, but multiplex immunohistochemistry/immunofluorescence had a higher positive predictive value than the other assays.

Continuing Medical Education

×